Skip to main content
Terug
Watch Compare

BioXcel Therapeutics, Inc.

Datakwaliteit: 100%
BTAI
Nasdaq Manufacturing Chemicals
€ 1,08
▼ € 0,02 (-1,82%)
Marktkapitalisatie: 29,24 M
Prijs
€ 1,08
Marktkapitalisatie
29,24 M
Dagbereik
€ 1,07 — € 1,15
52-Weeksbereik
€ 1,06 — € 8,08
Volume
774.689
Openen € 1,08
50D / 200D Gem.
€ 1,55
30,21% below
50D / 200D Gem.
€ 2,26
52,23% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -57,62 M
Capital efficient — spends only 0,00% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-71,67%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-10887,38%
Op. Margin-7859,97%

Veiligheid

Debt / Equity
N/A
Current Ratio1,17
Interest Coverage-3,29

Waardering

PE (TTM)
-0,42
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,4 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -10887,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -71,67% Revenue Growth (3Y) -31,79%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 642.000,0 Net Income (TTM) -69,90 M
ROE N/A ROA -198,06%
Gross Margin N/A Operating Margin -7859,97%
Net Margin -10887,38% Free Cash Flow (TTM) -57,62 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,17
Interest Coverage -3,29 Asset Turnover 0,02
Working Capital 6,60 M Tangible Book Value -88,92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,42 Forward P/E N/A
P/B Ratio N/A P/S Ratio 45,55
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -197,04%
Market Cap 29,24 M Enterprise Value 102,19 M
Per Share
EPS (Diluted TTM) -5,73 Revenue / Share 0,02
FCF / Share -2,13 OCF / Share -2,13
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 82,43%
SBC-Adj. FCF -61,80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 642.000,0 2,27 M 1,38 M 375.000,0 —
Net Income -69,90 M -59,60 M -179,05 M -165,76 M -106,93 M
EPS (Diluted) -5,73 -23,51 -6,15 -5,92 -4,05
Gross Profit — — — — —
Operating Income -50,46 M -67,25 M -171,78 M -159,65 M -106,94 M
EBITDA — — — — —
R&D Expenses 30,25 M 30,44 M 84,33 M 91,24 M 52,71 M
SG&A Expenses 20,49 M 34,49 M 83,41 M 68,76 M —
D&A — — — — 297.000,0
Interest Expense 15,33 M 14,66 M 13,31 M 8,21 M 40.000,0
Income Tax 0,0 0,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 44,92 M 38,34 M 73,70 M 205,85 M 239,44 M
Total Liabilities 140,38 M 131,44 M 130,21 M 129,08 M 17,77 M
Shareholders' Equity -95,46 M -93,10 M -56,51 M 76,78 M 221,67 M
Total Debt 109,59 M 102,51 M 100,60 M 93,05 M —
Cash & Equivalents 28,42 M 29,85 M 65,22 M 193,73 M 232,97 M
Current Assets 44,69 M 37,39 M 72,14 M 202,87 M 236,81 M
Current Liabilities 53,93 M 22,23 M 27,27 M 32,90 M 16,67 M